1
|
Ma D, Cardoso MJ, Zuluaga MA, Modat M, Powell NM, Wiseman FK, Cleary JO, Sinclair B, Harrison IF, Siow B, Popuri K, Lee S, Matsubara JA, Sarunic MV, Beg MF, Tybulewicz VLJ, Fisher EMC, Lythgoe MF, Ourselin S. Substantially thinner internal granular layer and reduced molecular layer surface in the cerebellar cortex of the Tc1 mouse model of down syndrome - a comprehensive morphometric analysis with active staining contrast-enhanced MRI. Neuroimage 2020; 223:117271. [PMID: 32835824 PMCID: PMC8417772 DOI: 10.1016/j.neuroimage.2020.117271] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 08/03/2020] [Accepted: 08/10/2020] [Indexed: 12/18/2022] Open
Abstract
Down Syndrome is a chromosomal disorder that affects the development of cerebellar cortical lobules. Impaired neurogenesis in the cerebellum varies among different types of neuronal cells and neuronal layers. In this study, we developed an imaging analysis framework that utilizes gadolinium-enhanced ex vivo mouse brain MRI. We extracted the middle Purkinje layer of the mouse cerebellar cortex, enabling the estimation of the volume, thickness, and surface area of the entire cerebellar cortex, the internal granular layer, and the molecular layer in the Tc1 mouse model of Down Syndrome. The morphometric analysis of our method revealed that a larger proportion of the cerebellar thinning in this model of Down Syndrome resided in the inner granule cell layer, while a larger proportion of the surface area shrinkage was in the molecular layer.
Collapse
Affiliation(s)
- Da Ma
- Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom; Centre for Advanced Biomedical Imaging, University College London, United Kingdom; School of Engineering Science, Simon Fraser University, Burnaby, Canada.
| | - Manuel J Cardoso
- Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, United Kingdom
| | - Maria A Zuluaga
- Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom; Data Science Department, EURECOM, France
| | - Marc Modat
- Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, United Kingdom
| | - Nick M Powell
- Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom; Centre for Advanced Biomedical Imaging, University College London, United Kingdom
| | - Frances K Wiseman
- UK Dementia Research Institute at University College London, UK London; Down Syndrome Consortium (LonDownS), London, United Kingdom
| | - Jon O Cleary
- Centre for Advanced Biomedical Imaging, University College London, United Kingdom; Department of Radiology, Guy´s and St Thomas' NHS Foundation Trust, United Kingdom; Melbourne Brain Centre Imaging Unit, Department of Medicine and Radiology, University of Melbourne, Melbourne, Australia
| | - Benjamin Sinclair
- Centre for Advanced Biomedical Imaging, University College London, United Kingdom
| | - Ian F Harrison
- Centre for Advanced Biomedical Imaging, University College London, United Kingdom
| | - Bernard Siow
- Centre for Advanced Biomedical Imaging, University College London, United Kingdom; The Francis Crick Institute, London, United Kingdom
| | - Karteek Popuri
- School of Engineering Science, Simon Fraser University, Burnaby, Canada
| | - Sieun Lee
- School of Engineering Science, Simon Fraser University, Burnaby, Canada
| | - Joanne A Matsubara
- Department of Ophthalmology & Visual Science, University of British Columbia, Vancouver, Canada
| | - Marinko V Sarunic
- School of Engineering Science, Simon Fraser University, Burnaby, Canada
| | - Mirza Faisal Beg
- School of Engineering Science, Simon Fraser University, Burnaby, Canada
| | - Victor L J Tybulewicz
- The Francis Crick Institute, London, United Kingdom; Department of Immunology and Inflammation, Imperial College, London, United Kingdom
| | | | - Mark F Lythgoe
- Centre for Advanced Biomedical Imaging, University College London, United Kingdom
| | - Sebastien Ourselin
- Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom; School of Biomedical Engineering & Imaging Sciences, King's College London, United Kingdom
| |
Collapse
|
2
|
Holmes HE, Powell NM, Ma D, Ismail O, Harrison IF, Wells JA, Colgan N, O'Callaghan JM, Johnson RA, Murray TK, Ahmed Z, Heggenes M, Fisher A, Cardoso MJ, Modat M, O'Neill MJ, Collins EC, Fisher EMC, Ourselin S, Lythgoe MF. Comparison of In Vivo and Ex Vivo MRI for the Detection of Structural Abnormalities in a Mouse Model of Tauopathy. Front Neuroinform 2017; 11:20. [PMID: 28408879 PMCID: PMC5374887 DOI: 10.3389/fninf.2017.00020] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Accepted: 02/27/2017] [Indexed: 11/15/2022] Open
Abstract
With increasingly large numbers of mouse models of human disease dedicated to MRI studies, compromises between in vivo and ex vivo MRI must be fully understood in order to inform the choice of imaging methodology. We investigate the application of high resolution in vivo and ex vivo MRI, in combination with tensor-based morphometry (TBM), to uncover morphological differences in the rTg4510 mouse model of tauopathy. The rTg4510 mouse also offers a novel paradigm by which the overexpression of mutant tau can be regulated by the administration of doxycycline, providing us with a platform on which to investigate more subtle alterations in morphology with morphometry. Both in vivo and ex vivo MRI allowed the detection of widespread bilateral patterns of atrophy in the rTg4510 mouse brain relative to wild-type controls. Regions of volume loss aligned with neuronal loss and pathological tau accumulation demonstrated by immunohistochemistry. When we sought to investigate more subtle structural alterations in the rTg4510 mice relative to a subset of doxycycline-treated rTg4510 mice, ex vivo imaging enabled the detection of more regions of morphological brain changes. The disadvantages of ex vivo MRI may however mitigate this increase in sensitivity: we observed a 10% global shrinkage in brain volume of the post-mortem tissues due to formalin fixation, which was most notable in the cerebellum and olfactory bulbs. However, many central brain regions were not adversely affected by the fixation protocol, perhaps due to our “in-skull” preparation. The disparity between our TBM findings from in vivo and ex vivo MRI underlines the importance of appropriate study design, given the trade-off between these two imaging approaches. We support the utility of in vivo MRI for morphological phenotyping of mouse models of disease; however, for subtler phenotypes, ex vivo offers enhanced sensitivity to discrete morphological changes.
Collapse
Affiliation(s)
- Holly E Holmes
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK
| | - Nick M Powell
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK.,Centre for Medical Image Computing, University College LondonLondon, UK
| | - Da Ma
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK.,Centre for Medical Image Computing, University College LondonLondon, UK
| | - Ozama Ismail
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK
| | - Ian F Harrison
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK
| | - Jack A Wells
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK
| | - Niall Colgan
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK
| | - James M O'Callaghan
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK
| | - Ross A Johnson
- Tailored Therapeutics, Eli Lilly and Company, Lilly Corporate CenterIndianapolis, IN, USA
| | | | - Zeshan Ahmed
- Molecular Pathology, Eli Lilly & Co. LtdWindlesham, UK
| | | | - Alice Fisher
- Molecular Pathology, Eli Lilly & Co. LtdWindlesham, UK
| | - M Jorge Cardoso
- Centre for Medical Image Computing, University College LondonLondon, UK
| | - Marc Modat
- Centre for Medical Image Computing, University College LondonLondon, UK
| | | | - Emily C Collins
- Tailored Therapeutics, Eli Lilly and Company, Lilly Corporate CenterIndianapolis, IN, USA
| | - Elizabeth M C Fisher
- Department of Neurodegenerative Disease, Institute of Neurology, University College LondonLondon, UK
| | | | - Mark F Lythgoe
- Division of Medicine, UCL Centre for Advanced Biomedical Imaging, University College LondonLondon, UK
| |
Collapse
|
3
|
Powell NM, Modat M, Cardoso MJ, Ma D, Holmes HE, Yu Y, O’Callaghan J, Cleary JO, Sinclair B, Wiseman FK, Tybulewicz VLJ, Fisher EMC, Lythgoe MF, Ourselin S. Fully-Automated μMRI Morphometric Phenotyping of the Tc1 Mouse Model of Down Syndrome. PLoS One 2016; 11:e0162974. [PMID: 27658297 PMCID: PMC5033246 DOI: 10.1371/journal.pone.0162974] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Accepted: 08/31/2016] [Indexed: 01/07/2023] Open
Abstract
We describe a fully automated pipeline for the morphometric phenotyping of mouse brains from μMRI data, and show its application to the Tc1 mouse model of Down syndrome, to identify new morphological phenotypes in the brain of this first transchromosomic animal carrying human chromosome 21. We incorporate an accessible approach for simultaneously scanning multiple ex vivo brains, requiring only a 3D-printed brain holder, and novel image processing steps for their separation and orientation. We employ clinically established multi-atlas techniques–superior to single-atlas methods–together with publicly-available atlas databases for automatic skull-stripping and tissue segmentation, providing high-quality, subject-specific tissue maps. We follow these steps with group-wise registration, structural parcellation and both Voxel- and Tensor-Based Morphometry–advantageous for their ability to highlight morphological differences without the laborious delineation of regions of interest. We show the application of freely available open-source software developed for clinical MRI analysis to mouse brain data: NiftySeg for segmentation and NiftyReg for registration, and discuss atlases and parameters suitable for the preclinical paradigm. We used this pipeline to compare 29 Tc1 brains with 26 wild-type littermate controls, imaged ex vivo at 9.4T. We show an unexpected increase in Tc1 total intracranial volume and, controlling for this, local volume and grey matter density reductions in the Tc1 brain compared to the wild-types, most prominently in the cerebellum, in agreement with human DS and previous histological findings.
Collapse
Affiliation(s)
- Nick M. Powell
- Translational Imaging Group, Centre for Medical Image Computing, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London NW1 2HE, United Kingdom
- Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, United Kingdom
- * E-mail:
| | - Marc Modat
- Translational Imaging Group, Centre for Medical Image Computing, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London NW1 2HE, United Kingdom
| | - M. Jorge Cardoso
- Translational Imaging Group, Centre for Medical Image Computing, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London NW1 2HE, United Kingdom
| | - Da Ma
- Translational Imaging Group, Centre for Medical Image Computing, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London NW1 2HE, United Kingdom
- Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, United Kingdom
| | - Holly E. Holmes
- Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, United Kingdom
| | - Yichao Yu
- Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, United Kingdom
| | - James O’Callaghan
- Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, United Kingdom
| | - Jon O. Cleary
- Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, United Kingdom
- Melbourne Brain Centre Imaging Unit, Department of Anatomy and Neuroscience, University of Melbourne, Parkville, Victoria 3052, Australia
| | - Ben Sinclair
- Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, United Kingdom
| | - Frances K. Wiseman
- Department of Neurodegenerative Disease, Institute of Neurology, University College, London WC1N 3BG, United Kingdom
| | - Victor L. J. Tybulewicz
- The Francis Crick Institute, Mill Hill Laboratory, London NW7 1AA, United Kingdom
- Imperial College, London W12 0NN, United Kingdom
| | - Elizabeth M. C. Fisher
- Department of Neurodegenerative Disease, Institute of Neurology, University College, London WC1N 3BG, United Kingdom
| | - Mark F. Lythgoe
- Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, United Kingdom
| | - Sébastien Ourselin
- Translational Imaging Group, Centre for Medical Image Computing, University College London, 3rd Floor, Wolfson House, 4 Stephenson Way, London NW1 2HE, United Kingdom
| |
Collapse
|
4
|
Ekins S, Diaz N, Chung J, Mathews P, McMurtray A. Enabling Anyone to Translate Clinically Relevant Ideas to Therapies. Pharm Res 2016; 34:1-6. [PMID: 27620174 DOI: 10.1007/s11095-016-2039-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 09/07/2016] [Indexed: 11/25/2022]
Abstract
How do we inspire new ideas that could lead to potential treatments for rare or neglected diseases, and allow for serendipity that could help to catalyze them? How many potentially good ideas are lost because they are never tested? What if those ideas could have lead to new therapeutic approaches and major healthcare advances? If a clinician or anyone for that matter, has a new idea they want to test to develop a molecule or therapeutic that they could translate to the clinic, how would they do it without a laboratory or funding? These are not idle theoretical questions but addressing them could have potentially huge economic implications for nations. If we fail to capture the diversity of ideas and test them we may also lose out on the next blockbuster treatments. Many of those involved in the process of ideation may be discouraged and simply not know where to go. We try to address these questions and describe how there are options to raising funding, how even small scale investments can foster preclinical or clinical translation, and how there are several approaches to outsourcing the experiments, whether to collaborators or commercial enterprises. While these are not new or far from complete solutions, they are first steps that can be taken by virtually anyone while we work on other solutions to build a more concrete structure for the "idea-hypothesis testing-proof of concept-translation-breakthrough pathway".
Collapse
Affiliation(s)
- Sean Ekins
- Collaborations Pharmaceuticals, Inc., 5616 Hilltop Needmore Road, Fuquay-Varina, Noth Carolina, 27526, USA.
- Phoenix Nest, Inc., P.O. BOX 150057, Brooklyn, New York, 11215, USA.
| | - Natalie Diaz
- Department of Neurology, Los Angeles Biomedical Research Institute, Torrance, California, 90502, USA
- Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California, 90095, USA
- Department of Neurology, Harbor-UCLA Medical Center, Torrance, California, 90509, USA
| | - Julia Chung
- Department of Psychiatry, Los Angeles Biomedical Research Institute, Torrance, California, 90502, USA
- Department of Psychiatry, Harbor-UCLA Medical Center, Torrance, California, 90509, USA
- Department of Psychiatry, David Geffen School of Medicine, University of California, Los Angeles, California, 90095, USA
| | - Paul Mathews
- Department of Neurology, Los Angeles Biomedical Research Institute, Torrance, California, 90502, USA
- Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California, 90095, USA
| | - Aaron McMurtray
- Department of Neurology, Los Angeles Biomedical Research Institute, Torrance, California, 90502, USA
- Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, California, 90095, USA
- Department of Neurology, Harbor-UCLA Medical Center, Torrance, California, 90509, USA
| |
Collapse
|
5
|
Belin-Rauscent A, Daniel ML, Puaud M, Jupp B, Sawiak S, Howett D, McKenzie C, Caprioli D, Besson M, Robbins TW, Everitt BJ, Dalley JW, Belin D. From impulses to maladaptive actions: the insula is a neurobiological gate for the development of compulsive behavior. Mol Psychiatry 2016; 21:491-9. [PMID: 26370145 DOI: 10.1038/mp.2015.140] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2015] [Revised: 07/15/2015] [Accepted: 08/10/2015] [Indexed: 02/06/2023]
Abstract
Impulsivity is an endophenotype of vulnerability for compulsive behaviors. However, the neural mechanisms whereby impulsivity facilitates the development of compulsive disorders, such as addiction or obsessive compulsive disorder, remain unknown. We first investigated, in rats, anatomical and functional correlates of impulsivity in the anterior insular (AI) cortex by measuring both the thickness of, and cellular plasticity markers in, the AI with magnetic resonance imaging and in situ hybridization of the immediate early gene zif268, respectively. We then investigated the influence of bilateral AI cortex lesions on the high impulsivity trait, as measured in the five-choice serial reaction time task (5-CSRTT), and the associated propensity to develop compulsivity as measured by high drinking levels in a schedule-induced polydipsia procedure (SIP). We demonstrate that the AI cortex causally contributes to individual vulnerability to impulsive-compulsive behavior in rats. Motor impulsivity, as measured by premature responses in the 5-CSRTT, was shown to correlate with the thinness of the anterior region of the insular cortex, in which highly impulsive (HI) rats expressed lower zif268 mRNA levels. Lesions of AI reduced impulsive behavior in HI rats, which were also highly susceptible to develop compulsive behavior as measured in a SIP procedure. AI lesions also attenuated both the development and the expression of SIP. This study thus identifies the AI as a novel neural substrate of maladaptive impulse control mechanisms that may facilitate the development of compulsive disorders.
Collapse
Affiliation(s)
- A Belin-Rauscent
- Department of Pharmacology, University of Cambridge, Cambridge, UK.,Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
| | - M-L Daniel
- Inserm CIC-1402, Université de Poitiers, Poitiers, France
| | - M Puaud
- Department of Pharmacology, University of Cambridge, Cambridge, UK.,Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
| | - B Jupp
- Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.,Department of Psychology, University of Cambridge, Cambridge, UK
| | - S Sawiak
- Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
| | - D Howett
- Department of Pharmacology, University of Cambridge, Cambridge, UK
| | - C McKenzie
- Department of Pharmacology, University of Cambridge, Cambridge, UK
| | - D Caprioli
- Behavioral Neuroscience Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
| | - M Besson
- Neurobiologie Intégrative des Systèmes Cholinergiques, Institut Pasteur, Paris, France
| | - T W Robbins
- Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.,Department of Psychology, University of Cambridge, Cambridge, UK
| | - B J Everitt
- Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.,Department of Psychology, University of Cambridge, Cambridge, UK
| | - J W Dalley
- Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.,Department of Psychology, University of Cambridge, Cambridge, UK.,Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - D Belin
- Department of Pharmacology, University of Cambridge, Cambridge, UK.,Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK
| |
Collapse
|
6
|
Sawiak SJ, Morton AJ. The Cambridge MRI database for animal models of Huntington disease. Neuroimage 2016; 124:1260-1262. [PMID: 25941090 DOI: 10.1016/j.neuroimage.2015.04.056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Revised: 04/23/2015] [Accepted: 04/26/2015] [Indexed: 12/11/2022] Open
Abstract
We describe the Cambridge animal brain magnetic resonance imaging repository comprising 400 datasets to date from mouse models of Huntington disease. The data include raw images as well as segmented grey and white matter images with maps of cortical thickness. All images and phenotypic data for each subject are freely-available without restriction from (http://www.dspace.cam.ac.uk/handle/1810/243361/). Software and anatomical population templates optimised for animal brain analysis with MRI are also available from this site.
Collapse
Affiliation(s)
- Stephen J Sawiak
- Wolfson Brain Imaging Centre, University of Cambridge, Box 65 Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Downing Street, Cambridge, UK; Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge, UK.
| | - A Jennifer Morton
- Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge, UK
| |
Collapse
|
7
|
Harris AP, Lennen RJ, Marshall I, Jansen MA, Pernet CR, Brydges NM, Duguid IC, Holmes MC. Imaging learned fear circuitry in awake mice using fMRI. Eur J Neurosci 2015; 42:2125-34. [PMID: 25943794 PMCID: PMC4744695 DOI: 10.1111/ejn.12939] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Revised: 04/20/2015] [Accepted: 04/30/2015] [Indexed: 01/04/2023]
Abstract
Functional magnetic resonance imaging (fMRI) of learned behaviour in ‘awake rodents’ provides the opportunity for translational preclinical studies into the influence of pharmacological and genetic manipulations on brain function. fMRI has recently been employed to investigate learned behaviour in awake rats. Here, this methodology is translated to mice, so that future fMRI studies may exploit the vast number of genetically modified mouse lines that are available. One group of mice was conditioned to associate a flashing light (conditioned stimulus, CS) with foot shock (PG; paired group), and another group of mice received foot shock and flashing light explicitly unpaired (UG; unpaired group). The blood oxygen level‐dependent signal (proxy for neuronal activation) in response to the CS was measured 24 h later in awake mice from the PG and UG using fMRI. The amygdala, implicated in fear processing, was activated to a greater degree in the PG than in the UG in response to the CS. Additionally, the nucleus accumbens was activated in the UG in response to the CS. Because the CS signalled an absence of foot shock in the UG, it is possible that this region is involved in processing the safety aspect of the CS. To conclude, the first use of fMRI to visualise brain activation in awake mice that are completing a learned emotional task is reported. This work paves the way for future preclinical fMRI studies to investigate genetic and environmental influences on brain function in transgenic mouse models of disease and aging.
Collapse
Affiliation(s)
- Anjanette P Harris
- BHF Centre for Cardiovascular Sciences, QMRI, University of Edinburgh, Edinburgh, EH16 4TJ, UK.,Centre for Cognitive Ageing and Cognitive Epidemiology, QMRI, University of Edinburgh, Edinburgh, UK
| | - Ross J Lennen
- BHF Centre for Cardiovascular Sciences, QMRI, University of Edinburgh, Edinburgh, EH16 4TJ, UK
| | - Ian Marshall
- Centre for Cognitive Ageing and Cognitive Epidemiology, QMRI, University of Edinburgh, Edinburgh, UK.,Neuroimaging Sciences, Centre for Clinical Brain Sciences, Edinburgh, UK
| | - Maurits A Jansen
- BHF Centre for Cardiovascular Sciences, QMRI, University of Edinburgh, Edinburgh, EH16 4TJ, UK
| | - Cyril R Pernet
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, Edinburgh, UK
| | - Nichola M Brydges
- Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK
| | - Ian C Duguid
- Integrative Physics, University of Edinburgh, Edinburgh, UK
| | - Megan C Holmes
- BHF Centre for Cardiovascular Sciences, QMRI, University of Edinburgh, Edinburgh, EH16 4TJ, UK.,Centre for Cognitive Ageing and Cognitive Epidemiology, QMRI, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
8
|
Barnes SA, Sawiak SJ, Caprioli D, Jupp B, Buonincontri G, Mar AC, Harte MK, Fletcher PC, Robbins TW, Neill JC, Dalley JW. Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia. Int J Neuropsychopharmacol 2014; 18:pyu010. [PMID: 25552430 PMCID: PMC4368881 DOI: 10.1093/ijnp/pyu010] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2014] [Accepted: 06/09/2014] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND N-methyl-d-aspartate receptor (NMDAR) dysfunction is thought to contribute to the pathophysiology of schizophrenia. Accordingly, NMDAR antagonists such as phencyclidine (PCP) are used widely in experimental animals to model cognitive impairment associated with this disorder. However, it is unclear whether PCP disrupts the structural integrity of brain areas relevant to the profile of cognitive impairment in schizophrenia. METHODS Here we used high-resolution magnetic resonance imaging and voxel-based morphometry to investigate structural alterations associated with sub-chronic PCP treatment in rats. RESULTS Sub-chronic exposure of rats to PCP (5mg/kg twice daily for 7 days) impaired sustained visual attention on a 5-choice serial reaction time task, notably when the attentional load was increased. In contrast, sub-chronic PCP had no significant effect on the attentional filtering of a pre-pulse auditory stimulus in an acoustic startle paradigm. Voxel-based morphometry revealed significantly reduced grey matter density bilaterally in the hippocampus, anterior cingulate cortex, ventral striatum, and amygdala. PCP-treated rats also exhibited reduced cortical thickness in the insular cortex. CONCLUSIONS These findings demonstrate that sub-chronic NMDA receptor antagonism is sufficient to produce highly-localized morphological abnormalities in brain areas implicated in the pathogenesis of schizophrenia. Furthermore, PCP exposure resulted in dissociable impairments in attentional function.
Collapse
Affiliation(s)
- Samuel A Barnes
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Stephen J Sawiak
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Daniele Caprioli
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Bianca Jupp
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Guido Buonincontri
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Adam C Mar
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Michael K Harte
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Paul C Fletcher
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Trevor W Robbins
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Jo C Neill
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill)
| | - Jeffrey W Dalley
- Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, CA (Dr Barnes); Behavioural and Clinical Neuroscience Institute and Department of Psychology, University of Cambridge, Downing St, Cambridge UK (Drs Sawiak, Caprioli, Jupp, Mar, Fletcher, Robbins, and Dalley); Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Sawiak and Buonincontri); Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK (Drs Fletcher and Dalley); Manchester Pharmacy School, University of Manchester, UK (Drs Harte and Neill).
| |
Collapse
|
9
|
Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA. Voxel-based morphometry with templates and validation in a mouse model of Huntington's disease. Magn Reson Imaging 2013; 31:1522-31. [PMID: 23835187 PMCID: PMC3919157 DOI: 10.1016/j.mri.2013.06.001] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Revised: 04/17/2013] [Accepted: 06/02/2013] [Indexed: 11/29/2022]
Abstract
Despite widespread application to human imaging, voxel-based morphometry (VBM), where images are compared following grey matter (GM) segmentation, is seldom used in mice. Here VBM is performed for the R6/2 model of Huntington's disease, a progressive neurological disorder. This article discusses issues in translating the methods to mice and shows that its statistical basis is sound in mice as it is in human studies. Whole brain images from live transgenic and control mice are segmented into GM maps after processing and compared to produce statistical parametric maps of likely differences. To assess whether false positives were likely to occur, a large cohort of ex vivo magnetic resonance brain images were sampled with permutation testing. Differences were seen particularly in the striatum and cortex, in line with studies performed ex vivo and as seen in human patients. In validation, the rate of false positives is as expected and these have no discernible distribution through the brain. The study shows that VBM successfully detects differences in the Huntington's disease mouse brain. The method is rapid compared to manual delineation and reliable. The templates created here for the mouse brain are freely released for other users in addition to an open-source software toolbox for performing mouse VBM.
Collapse
Affiliation(s)
- Stephen J Sawiak
- Wolfson Brain Imaging Centre, University of Cambridge, Box 65 Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK; Behavioural and Clinical Neuroscience Institute, Department of Experimental Psychology, Cambridge, CB2 3EB, UK
| | | | | | | | | |
Collapse
|